Management of bipolar depression with lamotrigine: an antiepileptic mood stabilizer
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The efficacy of lamotrigine in the treatment of focal epilepsies have already been reported in several case reports and open studies, which is thought to act by inhibiting glutamate release through voltage-sensitive sodium channels blockade and neuronal membrane stabilization. However, recent findings have also illustrated the importance of lamotrigine in alleviating the depressive symptoms of bipolar disorder, without causing mood destabilization or precipitating mania. Currently, no mood stabilizers are available having equal efficacy in the treatment of both mania and depression, two of which forms the extreme sides of the bipolar disorder. Lamotrigine, a well established anticonvulsant has received regulatory approval for the treatment and prevention of bipolar depression in more than 30 countries worldwide. Lamotrigine, acts through several molecular targets and overcomes the major limitation of other conventional antidepressants by stabilizing mood from "below baseline" thereby preventing switches to mania or episode acceleration, thus being effective for bipolar I disorder. Recent studies have also suggested that these observations could also be extended to patients with bipolar II disorder. Thus, lamotrigine may supposedly fulfill the unmet requirement for an effective depression mood stabilizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder
Judd, L. L., Akiskal, H. S., Schettler, P. J., Endicott, J., Maser, J., Solomon, D. A., Leon, A. C., Rice, J. A., & Keller, M. B. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.6.530 · Cited by 2,106
Grande, I., Berk, M., Birmaher, B., & Vieta, E. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00241-x · Cited by 1,710
Judd, L. L., Akiskal, H. S., Schettler, P. J., Coryell, W., Endicott, J., Maser, J. D., Solomon, D. A., Leon, A. C., & Keller, M. B. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.3.261 · Cited by 1,243 · cited 11×
“Pharmacol.”
BackgroundInfluentialCalabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Forced swimming test in mice: A review of antidepressant activity
Petit-Demouliere, B., Chenu, F., & Bourin, M. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2048-7 · Cited by 1,003 · cited 1×
“…results of which showed convincing evidence in the reduction of immobility time in the forced swimming test, the effect of which is mediated by an interaction with the noradrenergic system, probably with postsynaptic α1- and α2-adrenoreceptors (Petit-Demouliere et al., 2005; Consoni et al., 2006).”
BackgroundSouery, D., Oswald, P., Massat, I., Bailer, U., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Serretti, A., et al. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0713 · Cited by 521 · cited 1×
“In case of a history of previous hospitalization, an increased risk of re hospitalization, treatment resistance, and depressive relapse was reported (Souery et al., 2007; Lin et al., 2008).”
BackgroundCalabrese, J. R., Suppes, T., Bowden, C. L., Sachs, G. S., Swann, A. C., McElroy, S. L., Kusumakar, V., Ascher, J. A., Earl, N. L., Greene, P. L., et al. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1106 · Cited by 498
A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders
Frye, M. A., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Speer, A. M., Osuch, E. A., Luckenbaugh, D. A., Corá-Locatelli, G., Leverich, G. S., & Post, R. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00004 · Cited by 446 · cited 1×
“The use of lamotrigine as an augmentation drug was suggested from the evidence of the efficacy of the drug in the treatment of major depressive disorders, which also includes refractory unipolar depression (Frye et al., 2000; Barbee and Jamhour, 2002; Rocha and Hara, 2003).”
BackgroundRao, J. S., Harry, G. J., Rapoport, S. I., & Kim, H. W. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.47 · Cited by 432 · cited 1×
“…E synthase) responsible for the conversion of arachidonic acid to pro-inflammatory Prostaglandin E2, greater expression of vesicular glutamate transporter I, as well as elevated levels of protein and m RNA in the rat frontal cortex (Hashimoto et al., 2007; Rao et al., 2007, 2010; Kim et al., 2011).”
BackgroundAnand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426 · cited 1×
“Lamotrigine was also found to suppress ketamine induced perceptual abnormalities in healthy human volunteers (Anand et al., 2000).”
BackgroundPaulus, W., Classen, J., Cohen, L. G., Large, C. H., Di Lazzaro, V., Nitsche, M., Pascual-Leone, A., Rosenow, F., Rothwell, J. C., & Ziemann, U. (2008) · Brain Stimulation · doi:10.1016/j.brs.2008.06.002 · Cited by 414 · cited 1×
“Application of TMS to the motor cortex showed that with the reduction in the excitability of the motor cortex, reduction of the BOLD response was consistent, which was in line with the sodium channel blocker effects (Paulus et al., 2008).”
ResultLópez-Figueroa, A. L., Norton, C. S., López-Figueroa, M. O., Armellini-Dodel, D., Burke, S., Akil, H., López, J. F., & Watson, S. J. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.09.017 · Cited by 296 · cited 1×
“The result of the same indicated that these subjects showed highly altered 5- HT receptor m-RNA expression giving more evidence to support the involvement of 5-HT receptors in the mechanism of action of lamotrigine in bipolar disorders (Lopez-Figueroa et al., 2004).”
ResultBipolar II disorder: arguments for and against a distinct diagnostic entity
Vieta, E., & Suppes, T. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00561.x · Cited by 200 · cited 1×
“Owing to this, the clinical output of bipolar II disorder can be improved by the proper long-term management of the depressive symptoms (Endicott et al., 2008; Vieta and Suppes, 2008).”
Barbosa, L., Berk, M., & Vorster, M. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0407 · Cited by 165
Stabilization of Mood From Below Versus Above Baseline in Bipolar Disorder: A New Nomenclature
Ketter, T., & Calabrese, J. R. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0210 · Cited by 161
Perspectives for the development of animal models of bipolar disorder
Machado-Vieira, R., Kapczinski, F., & Soares, J. C. (2004) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.10.015 · Cited by 158 · cited 1×
“The animal models that have been proposed was found only to be partially matching the bipolar illness and in such case modeling of either depression or maniac behavior could be achieved, but not both (Machado-Vieira et al., 2004).”
BackgroundUnholzer, S., & Haen, E. (2015) · Pharmacopsychiatry · doi:10.1055/s-0035-1559635 · Cited by 22
Cited by
Bahji, A., Ermacora, D., Stephenson, C., Hawken, E. R., & Vazquez, G. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.03.030 · Cited by 139
Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder
Marinova, Z., Chuang, D.-M., & Fineberg, N. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170320104237 · Cited by 83
Morbidity in depressive disorders
Baldessarini, R. J., Forte, A., Selle, V., Sim, K., Tondo, L., Undurraga, J., & Vázquez, G. H. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000448661 · Cited by 63
Metadata
- Authors
- Prabhavalkar, K. S., Poovanpallil, N. B., & Bhatt, L. K.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2015-10-23
- Volume
- 6
- Pages
- 242-242
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2105670269
- Cited by
- 70
- References
- 17
- FWCI
- 3.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.